Evidence map›Paper›PMID 30474721›Full record

Observational studyRheumatology international2019

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.

Vicenç Torrente-Segarra, Manuel Fernandez Prada, Rosa Expósito Moliner, Noemí Patricia Garrido Puñal, Amalia Sánchez-Andrade Fernández, José Ramón Lamua Riazuelo, Alejandro Olivé, Juan Víctor Tovar Beltrán, RENACER Study Group (REgistro NAcional CERtolizumab)

Abstract readLetterObservational Study
PubMed Publisher
In one paragraph

Observational study in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vicenç Torrente-SegarraRheumatology Department, Hospital General Hospitalet-Sant Joan Despí Moisès Broggi, C/Avinguda Josep Molins 29-41, 08906, Hospitalet Llobregat, Catalunya, Spain. vtorrente@hsjdbcn.org.
Manuel Fernandez PradaRheumatology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Rosa Expósito MolinerRheumatology Department, Hospital Comarcal Laredo, Laredo, Spain.
Noemí Patricia Garrido PuñalRheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Amalia Sánchez-Andrade FernándezRheumatology Department, Complejo Hospital Universitario Lucus Augusti, Lugo, Spain.
José Ramón Lamua RiazueloRheumatology Department, Hospital Universitario de Henares, Alcalá de Henares, Spain.
Alejandro OlivéRheumatology Department, Hospital Germans Tries i Pujol, Badalona, Spain.
Juan Víctor Tovar BeltránRheumatology Department, Hospital General Universitario de Elche, Elche, Spain.
RENACER Study Group (REgistro NAcional CERtolizumab)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedArthritis, RheumatoidCertolizumab PegolFemaleHumansMaleMiddle AgedProspective StudiesCertolizumab PegolEffectivenessRheumatoid arthritisSafetyTumor necrosis factor inhibitors

Identifiers

PMID30474721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.